- Trial phase
- Phase 1/2a
- Time to market
- Several years away, still in Phase 1/2a with no regulatory filing submitted. If Phase 2a data are positive, a Phase 3 program would likely take 2-3+ years, followed by an FDA submission. Best-case timeline to potential approval is likely 2029-2030 at the earliest.
- Why 4/10
- No PDUFA or pivotal-readout date is scheduled within the next ~12 months. The next catalyst is the initiation of the post-incretin maintenance trial (expected Q4 2026), a soft event. Phase 2a combination and monotherapy data readouts are the next meaningful catalysts but lack specific dates. With the stock already down ~81% YTD and no hard binary catalyst on the calendar, the impact score is capped at 4.
The next catalyst is the initiation of the post-incretin maintenance trial, expected in Q4 2026 (imminent). Beyond that, Phase 2a combination-trial data (WVE-007 + tirzepatide) and 12-month monotherapy data are the next meaningful readouts, though no specific dates are set. A positive maintenance-trial initiation or combination data could re-rate the stock from its depressed levels, but the high short interest (~10.7% of outstanding) and intense GLP-1 competition mean any miss would likely be punished severely.
Price Chart
Executive Summary
WVE-007 is Wave Life Sciences' investigational GalNAc-siRNA targeting INHBE for obesity, with a novel mechanism that promotes fat loss while preserving muscle mass, differentiating it from GLP-1 drugs. Phase 1 data showed a single 240 mg dose reduced visceral fat by ~14% at six months with a 2% increase in lean mass, and durable Activin E suppression supports once- or twice-yearly dosing. Phase 2a monotherapy and combination (with tirzepatide) trials are underway, and a post-incretin maintenance trial is expected to start imminently. The stock trades near its 52-week low (~$3.21), down ~81% YTD, reflecting intense competition from Novo Nordisk and Eli Lilly and investor disappointment that early weight-loss numbers were modest. The company has $431M cash (runway into Q3 2028) and a strong-buy analyst consensus with a mean price target of ~$17.68, but the drug remains years from any regulatory filing.
How It Works
WVE-007 is a synthetic RNA molecule (siRNA) that travels to the liver and silences a gene called INHBE, which produces a protein called Activin E that normally tells the body to store fat. By turning off this signal, WVE-007 releases the brake on fat burning, causing the body to burn fat (especially dangerous visceral belly fat) while preserving or even building muscle. Unlike popular GLP-1 obesity drugs (like Wegovy or Zepbound) that work by suppressing appetite in the brain, WVE-007 works directly on fat metabolism and is designed to be injected just once or twice a year.
Trial Status
The Phase 1 single-ascending-dose (SAD) portion of the INLIGHT trial (NCT06842186) is complete with positive interim data reported Dec 2025 and Mar 2026. Phase 2a monotherapy (12-month) is ongoing. A Phase 2a combination trial with tirzepatide was initiated in September 2026. A post-incretin maintenance trial is expected to start in Q4 2026.
The Two-Sided Case
Upcoming Catalysts
- Initiation of post-incretin maintenance trial (expected Q4 2026, imminent)
- Phase 2a combination (WVE-007 + tirzepatide) data readout (no specific date)
- Phase 2a monotherapy 12-month data (no specific date)
- Q3 2026 earnings call (October 27, 2026, today)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Wave Life Sciences USA, Inc. PRESS-RELEASE WVE ·Originating report